GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Eurofins Scientific SE (OTCPK:ERFSF) » Definitions » Capex-to-Operating-Cash-Flow

Eurofins Scientific SE (Eurofins Scientific SE) Capex-to-Operating-Cash-Flow : 0.42 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Eurofins Scientific SE Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Eurofins Scientific SE's Capital Expenditure for the six months ended in Dec. 2023 was $-313.41 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2023 was $746.78 Mil.

Hence, Eurofins Scientific SE's Capex-to-Operating-Cash-Flow for the six months ended in Dec. 2023 was 0.42.


Eurofins Scientific SE Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Eurofins Scientific SE's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eurofins Scientific SE Capex-to-Operating-Cash-Flow Chart

Eurofins Scientific SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.48 0.29 0.34 0.58 0.54

Eurofins Scientific SE Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.58 0.58 0.79 0.42

Competitive Comparison of Eurofins Scientific SE's Capex-to-Operating-Cash-Flow

For the Diagnostics & Research subindustry, Eurofins Scientific SE's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eurofins Scientific SE's Capex-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Eurofins Scientific SE's Capex-to-Operating-Cash-Flow falls into.



Eurofins Scientific SE Capex-to-Operating-Cash-Flow Calculation

Eurofins Scientific SE's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-599.891) / 1110.033
=0.54

Eurofins Scientific SE's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-313.413) / 746.783
=0.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eurofins Scientific SE  (OTCPK:ERFSF) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Eurofins Scientific SE Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Eurofins Scientific SE's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Eurofins Scientific SE (Eurofins Scientific SE) Business Description

Traded in Other Exchanges
Address
23 Val Fleuri, Luxembourg, LUX, L-1526
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 900 laboratories in 61 countries. Its revenue from Europe, North America, and the Rest of the World contribute approximately 50%, 40%, and 10% of total revenue respectively. Its main business activities are food and environmental testing, biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.

Eurofins Scientific SE (Eurofins Scientific SE) Headlines